Navigation Links
Developed new method to diagnose hereditary breast and ovarian cancer

Researchers of the Catalan Institute of Oncology (ICO) at the Bellvitge Biomedical Research Institute (IDIBELL) have developed and validated a new method to diagnose hereditary breast and ovarian cancer syndrome based on mass sequencing of BRCA1 and BRCA2 genes. The model is based on a genetic and bioinformatic analysis which has been proved very effective. The new protocol has been described in an article published in the European Journal of Human Genetics.

In recent years, new advances in sequencing techniques have involved the development of new platforms for nucleic acid sequencing, called mass sequencing platforms or next-generation sequencing. These technological improvements have brought a revolution in biomedical research, in the field of genetics and genomics. The emergence of next-generation sequencers and the possibility of combining samples from different patients using identifiers have allowed to adapt these new technologies in the field of the genetic diagnosis.

Using a platform of last generation mass sequencing, the team led by the researcher Conxi Lzaro, from the Hereditary Cancer Program at the ICO and IDIBELL, has developed a comprehensive protocol that allows to sequence all coding and adjacent regions of BRCA1 and BRCA2 genes, responsible for hereditary breast and ovarian cancer syndrome.

Mass sequencing algorithm

"This approach allows to identify all point mutations and small deletions and insertions analyzed, even in regions of high technical difficulty, such as homopolymeric regions", explains the ICO-IDIBELL researcher. The protocol developed is an own algorithm of mass sequencing and bioinformatics analysis that has been shown to be very efficient to detect all existing mutations and to eliminate false positives.

The validation of this algorithm to diagnose hereditary breast and ovarian cancer syndrome has shown a sensitivity and specificity of 100% in the analyzed samples, while reducing costs and time for obtaining the results.

Furthermore, the research team led by Lzaro has implemented the use of this approach for the responsible genes for hereditary colorectal cancer, such as familial polyposis and Lynch syndrome.

Up to ten percent of cancers are hereditary, which means that the genetic mutations predisposing to various types of tumors are transmitted from parents to offspring. The identification of these mutations is very important to prevent the occurrence of tumors in people who have familial predisposition.

The hereditary breast and ovarian cancer syndrome is one of the hereditary cancer types that affects more people. The disease is caused by mutations in the BRCA1 and BRCA2 genes. These mutations are also associated with other kind of cancers.

Contact: Ral Toran
IDIBELL-Bellvitge Biomedical Research Institute

Related medicine news :

1. Research shows efficacy of treatment model developed at Women & Infants
2. Power generation technology based on piezoelectric nanocomposite materials developed by KAIST
3. AGA releases first independently developed ABIM-approved Practice Improvement Module in GI
4. FDA clears test developed in partnership with VCU researcher
5. National Actos Attorneys File Lawsuit on Behalf of Louisiana Woman who Developed Bladder Cancer Allegedly Due to The Diabetes Drug Actos
6. New Facebook app to detect pedophiles and criminals developed by Ben-Gurion U. researchers
7. Clinical trials start for stroke drug developed by Scripps Research, USC, and ZZ Biotech
8. Heroes of Chemistry: Developed new drugs and technology to cut heating and cooling bills
9. Multi-functional anti-inflammatory/anti-allergic developed by Hebrew University researcher
10. Strategy developed to improve delivery of medicines to the brain
11. Models developed from the PLCO may help identify at-risk patients for adverse smoking outcomes
Post Your Comments:
(Date:12/1/2015)... ... , ... It’s official: Tattoo taboo is a thing of the past. One ... (a whopping one in three aged 18 to 25 is inked). As tattoos transition ... ink. In fact, RealSelf , the world’s largest community for learning and sharing ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... technicians must mark the film for accurate interpretation by the radiologist. The marking ... an inventor from Sacramento, Calif., has found a way to alleviate this problem. ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... it has been selected as a finalist in this year’s Fierce Innovation Awards: ... Next IT Healthcare was recognized as a finalist in the category of Digital ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... the Field for Effective Post-Affiliation Integration ,” addresses a main “pain point” for ... deliver the anticipated results, once a deal is signed. This quick-read guidance ...
(Date:12/1/2015)... China (PRWEB) , ... December 01, 2015 , ... Nurotron ... result in its largest order to date. , The order will be from ... systems. Nurotron’s Venus Cochlear Implant System is an effective solution for children and adults ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Sweden , December 1, 2015 ... Cancer Study Group (IBCSG, Bern ) and ... to be part of a state of the art trial, ... --> --> The study, ... treated with anti-hormonal therapy in combination with palbociclib, a cancer ...
(Date:11/30/2015)... BASEL, Switzerland , Dec. 1, 2015 ... through its wholly-owned UK subsidiary Proximagen Ltd., today announced ... novel, oral small molecule inhibitor of Vascular Adhesion Protein ... in the treatment of inflammatory disease. The VAP-1 inhibitor ... --> --> Under the terms ...
(Date:11/30/2015)... Asia,s largest exhibition and conference dedicated to the Medical Device ... 22 nd April 2016. --> --> ... --> -->   --> --> ... population and the government back up, the Medical Device is one of the ... . With the aging population and the government back up, the Medical ...
Breaking Medicine Technology: